

[Patient Letter: For patients with squamous cell lung cancer currently receiving treatment on **S1900A**]

PATIENT INFORMATION LETTER

S1900A Cohort 1 (squamous cell lung cancer) was permanently closed to accrual on November 16, 2020 as the study met prespecified futility threshold at the planned interim analysis.

You are participating in a SWOG Cancer Research Network (SWOG) research study (**S1900A**) for advanced non-small cell lung cancer and you have been receiving treatment with rucaparib. It was stated in your Consent Form that you would be given any new information that might affect your health and/or your willingness to continue in the study. We, the SWOG study investigators, have new information regarding the effectiveness of rucaparib for patients with squamous cell lung cancer in the study. The study team reviewed the patient data to date and did not find that rucaparib was sufficiently active in patients with squamous cell lung cancer to continue enrolling patients to this study.

You are currently receiving rucaparib, and you can continue to receive the drug if you are experiencing clinical benefit, you agree to continue treatment, and if you and your physician feel that it is in your best interest to continue the treatment. You will continue to be followed as described in your Consent Form, whether you decide to continue or discontinue study treatment. If your cancer gets worse, you should stop receiving the treatment.

Should you and your physician decide to stop the treatment, you will continue to be followed off study treatment and further treatment options will be discussed by your treating physician.

We have greatly appreciated your participation in the trial. The results from this research study will contribute to the knowledge of how best to treat patients with advanced non-small cell lung cancer. You should discuss any questions you have about this "Patient Information Letter" with your treating physician.

Thank you very much for your participation.

Sincerely,

Roy Herbst, M.D., Ph.D.
Mary Redman, Ph.D.

Jonathan W. Riess, M.D.
Paul Wheatley-Price, M.D.